Home|Journals|Articles by Year|Audio Abstracts

Original Article

Eicosapentaenoic Acid Blocks Cyclosporine A-Induced Pancreatic Dysfunction but not Immunosuppression

Takashi Majima, Kazuki Sasaki, Hiroshi Ohara, Norio Takahashi.


Cyclosporine A (CsA) treatment often causes post-transplant diabetes mellitus. We aimed to determine whether eicosapentaenoic acid (EPA) could improve CsA-induced pancreatic dysfunction, while still maintaining its immunosuppressive activity. EPA did ameliorate impaired glucose tolerance and pancreatic islet vacuolation caused by CsA. EPA, however, did not recover the impairment of lipopolysaccharide-induced pancreatic NFATc3 activation induced by CsA, suggesting that it did not impair CsA’s immunosuppressive activity. CsA is an important immunosuppressant drug used to prevent transplant rejection. We believe that our study makes a significant contribution to the literature because it identifies EPA as a potential treatment to counter the negative side effects of CsA use, while still maintaining its desired activity.

Key words: CsA, islet cell vacuolation, glucose intolerance, EPA, NFAT

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.